Gilenya

( DrugBank: - / KEGG DRUG: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
13	多発性硬化症／視神経脊髄炎	107

告示番号	疾患名（ページ内リンク）	臨床試験数
14	慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー	2

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01786174 (ClinicalTrials.gov)	August 2013	4/2/2013	Gilenya in Amyotrophic Lateral Sclerosis (ALS)	Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patien ...	Amyotrophic Lateral Sclerosis	Drug: Gilenya;Other: Placebo	Massachusetts General Hospital	ALS Therapy Development Institute	Completed	18 Years	N/A	All	30	Phase 2	United States

First Previous1Next Last

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 10 of 107 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-004128-41-PT (EUCTR)	20/05/2022	21/09/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Austr ...
2	EUCTR2020-004128-41-DE (EUCTR)	14/04/2022	08/10/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Portugal;Serbia;Greece;Spain;Ukraine;Russian Federation;Switzerland;Italy;France;Austr ...
3	EUCTR2020-004128-41-AT (EUCTR)	28/03/2022	01/12/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Denma ...
4	EUCTR2020-004128-41-ES (EUCTR)	21/02/2022	27/07/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Austr ...
5	EUCTR2020-004128-41-BG (EUCTR)	15/02/2022	15/10/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Denma ...
6	EUCTR2020-004128-41-NL (EUCTR)	22/12/2021	14/09/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Austr ...
7	EUCTR2020-004128-41-BE (EUCTR)	10/12/2021	10/12/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Denma ...
8	EUCTR2020-004128-41-GR (EUCTR)	23/11/2021	06/10/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Switzerland;Italy;France;Austr ...
9	EUCTR2020-004128-41-IT (EUCTR)	11/10/2021	07/10/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: GILENYA- 0.5 MG - CAPSULE RIGIDE - USO ORALE Product Name: N/A Product Code: [N/A] INN or P ...	F. HOFFMANN - LA ROCHE LTD.	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Austr ...
10	EUCTR2020-004128-41-PL (EUCTR)	04/10/2021	13/09/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Austr ...

First Previous1 2 3 4 5…11Next Last

14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー

臨床試験数 : 175 / 薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-005280-24-GR (EUCTR)	17/10/2012	24/09/2012	Evaluate efficacy and safety of fingolimod 0.5 mgorally once daily versus placebo in chronicinflamma ...	A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the ef ...	Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) MedDRA version: 15.0;Level: PT;Clas ...	Trade Name: Gilenya Product Name: fingolimod Product Code: FTY720I INN or Proposed INN: fingolimod Other ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	156	Phase 2;Phase 3	United States;Greece;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Belgium;Poland;A ...
2	EUCTR2011-005280-24-ES (EUCTR)	19/09/2012	07/08/2012	Evaluate efficacy and safety of fingolimod 0.5 mg orally once daily versus placebo in chronic inflam ...	A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the ef ...	Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) MedDRA version: 14.1;Level: PT;Clas ...	Trade Name: GILENYA0,5 mg cápsulas duras Product Name: fingolimod Product Code: FTY720I INN or Proposed ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	156	Phase 2;Phase 3	United States;Greece;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Belgium;A ...

First Previous1Next Last